PURPOSE: The purpose of this study was to investigate the potential of [1-(11)C]acetate (AC) as a metabolic tracer for renal cell cancer in human subjects. METHODS: Twenty-one patients with suspected kidney tumours were investigated with AC and dynamic PET. AC uptake was scored on a five-step scale. Tumour localisation was known from CT/MRI. Histology was available in 18/21 patients. The results in these 18 patients are reported. RESULTS: AC uptake by the tumour was less than (n=11), equal to (n=5) or higher than (n=2) uptake in the surrounding renal parenchyma. Histological tumour types showed a typical distribution, with a predominance of clear cell carcinomas (n=14) and only a small number of papillary cell carcinomas (n=2) and oncocytomas (n=2). Only the benign oncocytomas were highly positive with AC. CONCLUSION: In most kidney tumours the AC accumulation was not higher than in normal kidney parenchyma. Therefore, AC PET cannot be recommend for the characterisation of a renal mass.
PURPOSE: The purpose of this study was to investigate the potential of [1-(11)C]acetate (AC) as a metabolic tracer for renal cell cancer in human subjects. METHODS: Twenty-one patients with suspected kidney tumours were investigated with AC and dynamic PET. AC uptake was scored on a five-step scale. Tumour localisation was known from CT/MRI. Histology was available in 18/21 patients. The results in these 18 patients are reported. RESULTS:AC uptake by the tumour was less than (n=11), equal to (n=5) or higher than (n=2) uptake in the surrounding renal parenchyma. Histological tumour types showed a typical distribution, with a predominance of clear cell carcinomas (n=14) and only a small number of papillary cell carcinomas (n=2) and oncocytomas (n=2). Only the benign oncocytomas were highly positive with AC. CONCLUSION: In most kidney tumours the AC accumulation was not higher than in normal kidney parenchyma. Therefore, AC PET cannot be recommend for the characterisation of a renal mass.
Authors: Michael A Blake; Margaret McKernan; Bindu Setty; Alan J Fischman; Peter R Mueller Journal: AJR Am J Roentgenol Date: 2006-01 Impact factor: 3.959
Authors: S Störkel; J N Eble; K Adlakha; M Amin; M L Blute; D G Bostwick; M Darson; B Delahunt; K Iczkowski Journal: Cancer Date: 1997-09-01 Impact factor: 6.860
Authors: Marc A Seltzer; Shamim A Jahan; Richard Sparks; David B Stout; Nagichettiar Satyamurthy; Magnus Dahlbom; Michael E Phelps; Jorge R Barrio Journal: J Nucl Med Date: 2004-07 Impact factor: 10.057
Authors: Jörg Kotzerke; Björn G Volkmer; Bernd Neumaier; Jürgen E Gschwend; Richard E Hautmann; Sven N Reske Journal: Eur J Nucl Med Mol Imaging Date: 2002-07-27 Impact factor: 9.236
Authors: Evelina Miele; Gian Paolo Spinelli; Federica Tomao; Angelo Zullo; Filippo De Marinis; Giulia Pasciuti; Luigi Rossi; Federica Zoratto; Silverio Tomao Journal: J Exp Clin Cancer Res Date: 2008-10-17